Intrahepatic cholangiocarcinoma (ICC) is the second most common primary
liver cancer, with a 5-year survival rate of <10%; effective
drug treatment for ICC is currently lacking.
Glucagon-like peptide-1 receptor (GLP-1R) is upregulated in ICC; however, the functions of GLP-1R in ICC remain unknown. In this study, the upregulation of GLP-1R was confirmed in ICC cells using reverse transcription-quantitative polymerase chain reaction and western blot analysis, and GLP-1R was determined to promote the migration and invasion of ICC cells using Transwell assays. This
tumor-promoting effect depended on the upregulation of epithelial-mesenchymal transformation-associated
proteins, which was mediated by the FoxO1 signaling pathway. It was also indicated that following
oxaliplatin treatment, the effects of GLP-1R on EMT and invasion were reversed. This functional reversion was associated with the reduced phosphorylation of S256 in forkhead box O1 (FoxO1) and an increase in the levels of unphosphorylated FoxO1. These findings suggest that
incretin-based
therapies may increase the risk of ICC
metastasis and should not be used solely for the treatment of patients with ICC.